52 Week Range
As of on the NASDAQ ∙ Minimum 15 minute delay
3M AVG Volume
52 Week High
52 Week Low
Shares Out (MIL)
Market Cap (MIL)
Dividend (Yield %)
Allogene Therapeutics Receives Ind Clearance From The U.S. Food And Drug Administration For Allo-715 In Combination With Nirogacestat In Relapsed/Refractory Multiple Myeloma
Allogene, Overland Form JV In Greater China To Develop, Commercialize AlloCAR T Cell Therapies
Allogene Therapeutics Announces Preclinical Findings Supporting Allo-605, First Anti-Bcma Turbocar T Cell Therapy
Allogene Therapeutics, Inc. is a clinical stage immuno-oncology company. The Company is focused on developing and commercializing of allogeneic T cell therapies for the treatment of cancer. It is involved in developing a pipeline of multiple allogeneic chimeric antigen receptor (CAR) T cell product candidates utilizing protein engineering, gene editing, gene insertion and T cell manufacturing technologies. Its T cell product candidates are designed to target and kill cancer cells. Its product candidate includes UCART19, ALLO-501, ALLO-715 and ALLO-647. The Company’s UCART19 is an allogeneic CAR T cell therapy that targets CD19. The Company’s ALLO-501 is an allogeneic anti-CD19 CAR T cell product candidate, which is designed for the treatment of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL). The Company’s ALLO-715 targets B-cell maturation antigen (BCMA) for the treatment of patients with R/R multiple myeloma.
Biotechnology & Drugs
210 E Grand Ave
SOUTH SAN FRANCISCO, CA
Arie S. Belldegrun
Executive Chairman of the Board
President, Chief Executive Officer, Co-Founder, Director
Joshua A. Kazam
Eric T. Schmidt
Chief Financial Officer
Rafael G. Amado
Executive Vice President - Research and Development, Chief Medical Officer
Price To Earnings (TTM)
Price To Sales (TTM)
Price To Book (MRQ)
Price To Cash Flow (TTM)
Total Debt To Equity (MRQ)
LT Debt To Equity (MRQ)
Return on Investment (TTM)
Return on Equity (TTM)
* ALLOGENE THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK
* ALLOGENE THERAPEUTICS ANNOUNCES COMMENCEMENT OF PUBLIC OFFERING OF COMMON STOCK
* ALLOGENE THERAPEUTICS, WITH COLLABORATOR SERVIER, REPORTS POSITIVE RESULTS FROM ITS PHASE 1 ALPHA STUDY OF ALLO-501 IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA AT AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING
Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including CVS Health, Regal Beloit and Zuora, on Thursday. HIGHLIGHT * CVS Health Corp : Credit Suisse raises to outperform from neutral * Dow Inc : HSBC cuts to hold...
* AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ABSTRACT REPORTS INITIAL ALLO-501 ALPHA PHASE 1 DATA IN RELAPSED/REFRACTORY NON-HODGKIN LYMPHOMA
Wall Street securities analysts on Thursday revised their ratings and price targets on several U.S.-listed companies, including Ashland Global Holdings, Lyft and Solaredge Technologies. HIGHLIGHTS * Ashland Global Holdings Inc. : JP Morgan raises to neutral from underweight...
* ALLOGENE THERAPEUTICS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS
* MAXCYTE AND ALLOGENE THERAPEUTICS SIGN CLINICAL AND COMMERCIAL LICENSE AGREEMENT TO ENABLE THE ADVANCEMENT OF ALLOGENEIC CAR T (ALLOCAR T™) THERAPIES
* ALLOGENE THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS
* Eikon search string for individual stock moves: * The Day Ahead newsletter: http://tmsnrt.rs/2ggOmBi * The Morning News Call newsletter: http://tmsnrt.rs/2fwPLTh U.S. stocks were on pace for their fifth day of losses on Friday, after weak U.S. jobs data in February added...
Moderna Inc's <MRNA.O> shares fell as much as 6 percent in an upsized market debut on Friday, taking a hit from a broader selloff in U.S. markets spurred by investor concerns over an economic slowdown amid renewed trade tensions.
Moderna Inc's shares fell as much as 6 percent in an upsized market debut on Friday, taking a hit from a broader selloff in the U.S. markets spurred by investors fretting over an economic slowdown.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.